39 results on '"Dobard, Charles"'
Search Results
2. Author Correction: Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
- Author
-
Young, Isabella C., Massud, Ivana, Cottrell, Mackenzie L., Shrivastava, Roopali, Maturavongsadit, Panita, Prasher, Alka, Wong-Sam, Andres, Dinh, Chuong, Edwards, Tiancheng, Mrotz, Victoria, Mitchell, James, Seixas, Josilene Nascimento, Pallerla, Aryani, Thorson, Allison, Schauer, Amanda, Sykes, Craig, De la Cruz, Gabriela, Montgomery, Stephanie A., Kashuba, Angela D. M., Heneine, Walid, Dobard, Charles W., Kovarova, Martina, Garcia, J. Victor, Garcίa-Lerma, J. Gerardo, and Benhabbour, S. Rahima
- Published
- 2024
- Full Text
- View/download PDF
3. Defining blood hematology reference values in female pig‐tailed macaques (Macaca nemestrina) using the Isolation Forest algorithm.
- Author
-
Kim, Daniel, Derton, Abigail, Khalil, George, Pan, Yi, Bachman, Shanon, Kelley, Kristen, Garcίa‐Lerma, Gerardo, Dobard, Charles W., and Daly, Michele B.
- Abstract
Background: Pig‐tailed macaques (PTMs) are commonly used as preclinical models to assess antiretroviral drugs for HIV prevention research. Drug toxicities and disease pathologies are often preceded by changes in blood hematology. To better assess the safety profile of pharmaceuticals, we defined normal ranges of hematological values in PTMs using an Isolation Forest (iForest) algorithm. Methods: Eighteen female PTMs were evaluated. Blood was collected 1–24 times per animal for a total of 159 samples. Complete blood counts were performed, and iForest was used to analyze the hematology data to detect outliers. Results: Median, IQR, and ranges were calculated for 13 hematology parameters. From all samples, 22 outliers were detected. These outliers were excluded from the reference index. Conclusions: Using iForest, we defined a normal range for hematology parameters in female PTMs. This reference index can be a valuable tool for future studies evaluating drug toxicities in PTMs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Weekly Oral Tenofovir Alafenamide Protects Macaques from Vaginal and Rectal Simian HIV Infection.
- Author
-
Massud, Ivana, Nishiura, Kenji, Ruone, Susan, Holder, Angela, Dinh, Chuong, Lipscomb, Jonathan, Mitchell, James, Khalil, George M., Heneine, Walid, Garcίa-Lerma, J. Gerardo, and Dobard, Charles W.
- Subjects
SIMIAN immunodeficiency virus ,HIV infections ,MACAQUES ,TENOFOVIR ,PRE-exposure prophylaxis ,ANTIRETROVIRAL agents - Abstract
Pre-exposure prophylaxis (PrEP) with a weekly oral regimen of antiretroviral drugs could be a suitable preventative option for individuals who struggle with daily PrEP or prefer not to use long-acting injectables. We assessed in macaques the efficacy of weekly oral tenofovir alafenamide (TAF) at doses of 13.7 or 27.4 mg/kg. Macaques received weekly oral TAF for six weeks and were exposed twice-weekly to SHIV vaginally or rectally on day 3 and 6 after each dose. Median TFV-DP levels in PBMCs following the 13.7 mg/kg dose were 3110 and 1137 fmols/10
6 cells on day 3 and 6, respectively. With the 27.4 mg/kg dose, TFV-DP levels were increased (~2-fold) on day 3 and 6 (6095 and 3290 fmols/106 cells, respectively). Both TAF doses (13.7 and 27.4 mg/kg) conferred high efficacy (94.1% and 93.9%, respectively) against vaginal SHIV infection. Efficacy of the 27.4 mg/kg dose against rectal SHIV infection was 80.7%. We estimate that macaque doses of 13.7 and 27.4 mg/kg are equivalent to approximately 230 and 450 mg of TAF in humans, respectively. Our findings demonstrate the effectiveness of a weekly oral PrEP regimen and suggest that a clinically achievable oral TAF dose could be a promising option for non-daily PrEP. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
5. Efficacy of Vaginally Administered Gel Containing Emtricitabine and Tenofovir Against Repeated Rectal Simian Human Immunodeficiency Virus Exposures in Macaques
- Author
-
Dobard, Charles W., Makarova, Natalia, West-Deadwyler, Rolieria, Taylor, Andrew, Dinh, Chuong, Martin, Amy, Lipscomb, Jonathan, Mitchell, James, Khalil, George, Garcia-Lerma, Gerardo, and Heneine, Walid
- Published
- 2018
6. Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques.
- Author
-
Daly, Michele B., Wong-Sam, Andres, Li, Linying, Krovi, Archana, Gatto, Gregory J., Norton, Chasity, Luecke, Ellen H., Mrotz, Victoria, Forero, Catalina, Cottrell, Mackenzie L., Schauer, Amanda P., Gary, Joy, Nascimento-Seixas, Josilene, Mitchell, James, van der Straten, Ariane, Heneine, Walid, Garcίa-Lerma, J. Gerardo, Dobard, Charles W., and Johnson, Leah M.
- Subjects
LONG-acting reversible contraceptives ,BIOABSORBABLE implants ,PHARMACOKINETICS ,MACAQUES ,UNPLANNED pregnancy ,HIV prevention ,PREGNANCY tests ,CONTROLLED release drugs - Abstract
The prevention of HIV and unintended pregnancies is a public health priority. Multi-purpose prevention technologies capable of long-acting HIV and pregnancy prevention are desirable for women. Here, we utilized a preclinical macaque model to evaluate the pharmacokinetics of biodegradable ε-polycaprolactone implants delivering the antiretroviral islatravir (ISL) and the contraceptive etonogestrel (ENG). Three implants were tested: ISL-62 mg, ISL-98 mg, and ENG-33 mg. Animals received one or two ISL-eluting implants, with doses of 42, 66, or 108 µg of ISL/day with or without an additional ENG-33 mg implant (31 µg/day). Drug release increased linearly with dose with median [range] plasma ISL levels of 1.3 [1.0–2.5], 1.9 [1.2–6.3] and 2.8 [2.3–11.6], respectively. The ISL-62 and 98 mg implants demonstrated stable drug release over three months with ISL-triphosphate (ISL-TP) concentr54ations in PBMCs above levels predicted to be efficacious for PrEP. Similarly, ENG implants demonstrated sustained drug release with median [range] plasma ENG levels of 495 [229–1110] pg/mL, which suppressed progesterone within two weeks and showed no evidence of altering ISL pharmacokinetics. Two of the six ISL-98 mg implants broke during the study and induced implant-site reactions, whereas no reactions were observed with intact implants. We show that ISL and ENG biodegradable implants are safe and yield sufficient drug levels to achieve prevention targets. The evaluation of optimized implants with increased mechanical robustness is underway for improved durability and vaginal efficacy in a SHIV challenge model. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir
- Author
-
Dobard, Charles W., Taylor, Andrew, Sharma, Sunita, Anderson, Peter L., Bushman, Lane R., Chuong, Dinh, Pau, Chou-Pong, Hanson, Debra, Wang, Lin, Garcia-Lerma, J. Gerardo, McGowan, Ian, Rohan, Lisa, and Heneine, Walid
- Published
- 2015
8. Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis
- Author
-
Makarova, Natalia, Henning, Tara, Taylor, Andrew, Dinh, Chuong, Lipscomb, Jonathan, Aubert, Rachael, Hanson, Debra, Phillips, Christi, Papp, John, Mitchell, James, McNicholl, Janet, Garcia-Lerma, Gerardo J., Heneine, Walid, Kersh, Ellen, and Dobard, Charles
- Published
- 2017
- Full Text
- View/download PDF
9. Assessment of penile erection methods in rhesus macaques to model pharmacokinetics of antiretroviral drugs and penile infection with simian immunodeficiency virus
- Author
-
Hayes, James, Powell, Nathaniel, Lathrop, George, Heneine, Walid, and Dobard, Charles W.
- Published
- 2016
- Full Text
- View/download PDF
10. SHIV SUSCEPTIBILITY CHANGES DURING THE MENSTRUAL CYCLE OF PIGTAIL MACAQUES: ABSTRACT #34
- Author
-
Kersh, Ellen N., Henning, Tara, Vishwanathan, Ajay S., Morris, Monica, Butler, Katherine, Adams, Debra R., Guenthner, Patricia, Srinivasan, Priya, Smith, James, Radzio, Jessica, Garcia-Lerma, Gerardo J., Dobard, Charles, Heneine, Walid, Hendry, Michael R., and McNicholl, Janet
- Published
- 2014
11. Development and optimization of a non-enzymatic method of leukocyte isolation from macaque tissues
- Author
-
Pereira, Lara E., Makarova, Natalia, Dobard, Charles, Aubert, Rachael D., Srinivasan, Priya, McNicholl, Janet, and Smith, James M.
- Published
- 2014
- Full Text
- View/download PDF
12. ASSESSING DRUG RESISTANCE EMERGENCE IN A MACAQUE MODEL OF ANTIRETROVIRAL PRE-EXPOSURE PROPHYLAXIS (PREP): Abstract #54
- Author
-
Dobard, Charles, Masciotra, Silvina, Lipscomb, Jonathan, Youngpairoj, Ae, Cong, Mian-er, Sharma, Sunita, Johnson, Jeffrey, Garcia-Lerma, Gerardo, and Heneine, & Walid
- Published
- 2011
13. Formulation of a microbicide gel with integrase inhibitor and evaluation of safety in female pig-tailed macaques: 007
- Author
-
Dobard, Charles, Parikh, Urvi, Sharma, Sunita, Hazuda, Daria, Jia, Hongwei, Smith, James, Rabe, Lorna, Garcia-Lerma, Gerardo J., Otten, Ron, and Heneine, Walid
- Published
- 2009
14. Pharmacokinetics of vaginally applied integrase inhibitors in macaques.
- Author
-
Nishiura, Kenji, Sharma, Sunita, Sterling, Mara, Makarova, Natalia, Martin, Amy, Dinh, Chuong, Mitchell, James, García-Lerma, J Gerardo, Heneine, Walid, and Dobard, Charles
- Subjects
INTEGRASE inhibitors ,MACAQUES ,PHARMACOKINETICS ,HIV prevention ,SIMIAN immunodeficiency virus ,RALTEGRAVIR ,MAGNITUDE (Mathematics) ,RNA virus infections ,ANTI-HIV agents ,RESEARCH ,ANIMAL experimentation ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,PRIMATES ,COMPARATIVE studies ,VAGINAL medication ,RESEARCH funding ,ENZYME inhibitors ,THERAPEUTICS - Abstract
Objectives: We conducted a detailed pharmacokinetic assessment in macaques treated with vaginal gels formulated with HIV integrase strand transfer inhibitors (INSTIs) to better understand drug distribution and identify INSTI concentrations associated with previously demonstrated in vivo protection against vaginal simian HIV challenge.Methods: Six macaques received vaginal gel containing 1% raltegravir (30 mg) once-weekly over 6 weeks. Following a washout period, five macaques received once-weekly gel containing 0.23% L-870,812 (7 mg). Drug concentrations were measured in plasma, mucosal fluids and vaginal tissues at baseline and 2, 5 and 24 h post-dosing.Results: The median maximum concentration (Cmax) for raltegravir and L-870,812 in plasma was below the limit of quantification and 41.1 ng/mL, respectively. The Cmax in vaginal fluids (1441 and 1250 μg/mL) and tissues (266.7 and 368.4 μg/g) was achieved 2-5 h after dosing, respectively. A similar half-life was observed for raltegravir and L-870,812 in vaginal fluids (8-10 h) and remained 3-4 orders of magnitude above the protein-adjusted IC95 (0.016 and 0.106 μg/mL, respectively) at 24 h. Drug concentrations in vaginal fluids correlated well with those in vaginal tissues (Pearson r ≥ 0.788). Both drugs were consistently detected in rectal fluids 2 h after vaginal dosing, albeit at much lower levels (31-92-fold) than those in vaginal fluids.Conclusions: To the best of our knowledge, this study provides the first data on INSTI levels in vaginal tissues associated with in vivo protection and demonstrates rectal drug distribution of INSTIs after vaginal dosing. These findings may inform dose selection for topical products with INSTIs for HIV prevention. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
15. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
- Author
-
Romano, Joseph W., Baum, Marc M., Demkovich, Zach R., Diana, Frank, Dobard, Charles, Feldman, Paul L., Garcia-Lerma, J. Gerardo, Grattoni, Alessandro, Gunawardana, Manjula, Ho, Duy-Khiet, Hope, Thomas J., Massud, Ivana, Milad, Mark, Moss, John A., Pons-Faudoa, Fernanda P., Roller, Shane, van der Straten, Ariane, Srinivasan, Selvi, Veazey, Ronald S., and Zane, Doris
- Abstract
The ability to successfully develop a safe and effective vaccine for the prevention of HIV infection has proven challenging. Consequently, alternative approaches to HIV infection prevention have been pursued, and there have been a number of successes with differing levels of efficacy. At present, only two oral preexposure prophylaxis (PrEP) products are available, Truvada and Descovy. Descovy is a newer product not yet indicated in individuals at risk of HIV-1 infection from receptive vaginal sex, because it still needs to be evaluated in this population. A topical dapivirine vaginal ring is currently under regulatory review, and a long-acting (LA) injectable cabotegravir product shows strong promise. Although demonstrably effective, daily oral PrEP presents adherence challenges for many users, particularly adolescent girls and young women, key target populations. This limitation has triggered development efforts in LA HIV prevention options. This article reviews efforts supported by the Bill & Melinda Gates Foundation, as well as similar work by other groups, to identify and develop optimal LA HIV prevention products. Specifically, this article is a summary review of a meeting convened by the foundation in early 2020 that focused on the development of LA products designed for extended delivery of tenofovir alafenamide (TAF) for HIV prevention. The review broadly serves as technical guidance for preclinical development of LA HIV prevention products. The meeting examined the technical feasibility of multiple delivery technologies, in vivo pharmacokinetics, and safety of subcutaneous (SC) delivery of TAF in animal models. Ultimately, the foundation concluded that there are technologies available for long-term delivery of TAF. However, because of potentially limited efficacy and possible toxicity issues with SC delivery, the foundation will not continue investing in the development of LA, SC delivery of TAF products for HIV prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
16. Long-Acting Cabotegravir Protects Macaques Against Repeated Penile Simian-Human Immunodeficiency Virus Exposures.
- Author
-
Dobard, Charles, Makarova, Natalia, Nishiura, Kenji, Dinh, Chuong, Holder, Angela, Sterling, Mara, Lipscomb, Jonathan, Mitchell, James, Deyounks, Frank, Garber, David, Khalil, George, Spreen, William, Heneine, Walid, and García-Lerma, J Gerardo
- Subjects
- *
MACAQUES , *IMMUNODEFICIENCY , *HETEROSEXUAL men , *CONFIDENCE intervals , *URETHRA , *RNA virus infections , *PYRIDINE , *BIOLOGICAL models , *RESEARCH , *HIV integrase inhibitors , *PENIS , *ANIMAL experimentation , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *PREVENTIVE health services , *PRIMATES , *COMPARATIVE studies , *CHEMOPREVENTION , *INFECTIOUS disease transmission - Abstract
We used a novel penile simian-human immunodeficiency virus (SHIV) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV acquisition in macaques. Twenty-two macaques were exposed to SHIV via the foreskin and urethra once weekly for 12 weeks. Of these, 6 received human-equivalent doses of CAB LA, 6 received oral emtricitabine/tenofovir disoproxil fumarate, and 10 were untreated. The efficacy of CAB LA was high (94.4%; 95% confidence interval, 58.2%-99.3%) and similar to that seen with oral emtricitabine/tenofovir disoproxil fumarate (94.0%; 55.1%-99.2%). The high efficacy of CAB LA in the penile transmission model supports extending the clinical advancement of CAB LA preexposure prophylaxis to heterosexual men. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Development of a repeat-exposure penile SHIV infection model in macaques to evaluate biomedical preventions against HIV.
- Author
-
Garber, David A., Mitchell, James, Adams, Debra, Guenthner, Patricia, Deyounks, Frank, Ellis, Shanon, Kelley, Kristen, Johnson, Ryan, Dobard, Charles, Heneine, Walid, and McNicholl, Janet
- Subjects
HIV prevention ,MACAQUES ,EPIDEMICS ,PENIS diseases ,FORESKIN - Abstract
Penile acquisition of HIV infection contributes substantially to the global epidemic. Our goal was to establish a preclinical macaque model of penile HIV infection for evaluating the efficacy of new HIV prevention modalities. Rhesus macaques were challenged once or twice weekly with consistent doses of SHIV
sf 162P3 (a chimeric simian-human immunodeficiency virus containing HIV env) ranging from 4–600 TCID50 (50% tissue culture infective dose), via two penile routes, until systemic SHIV infection was confirmed. One route exposed the inner foreskin, glans and urethral os to virus following deposition into the prepuce (foreskin) pouch. The second route introduced the virus non-traumatically into the distal urethra only. Single-route challenges resulted in dose-dependent rates of SHIV acquisition informing selection of optimal SHIV dosing. Concurrent SHIV challenges via the prepuce pouch (200 TCID50 ) and urethra (16 TCID50 ) resulted in infection of 100% (10/10) animals following a median of 2.5 virus exposures (range, 1–12). We describe the first rhesus macaque repeat-exposure SHIV challenge model of penile HIV acquisition. Utilization of the model should further our understanding of penile HIV infection and facilitate the development of new HIV prevention strategies for men. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
18. VAGINAL PrEP EFFICACY OF BIODEGRADABLE ISLATRAVIR IMPLANTS IN MACAQUES.
- Author
-
Daly, Michele B., Kim, Daniel, Linying Li, Krovi, Archana, Norton, Chasity, Forero, Catalina, Brake, Marie, Dinh, Chuong, Edwards, Tiancheng, Cottrell, Mackenzie, Heneine, Walid, Garcia-Lerma, Gerardo, Dobard, Charles, Mitchell, James, and Johnson, Leah
- Published
- 2023
19. Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling.
- Author
-
Kersh, Ellen N., Henning, Tara R., Dobard, Charles, Heneine, Walid, and McNicholl, Janet M.
- Abstract
Vaginal SHIV
SF162P3 acquisition in pigtail macaques ( Macaca nemestrina) is dependent on time point during the menstrual cycle. Susceptibility is higher around menstruation and lower at ovulation in mid cycle. This complicates the design of repeat low-dose (RLD) SHIV exposure studies because virus challenges given during low susceptibility periods have lower chances to infect. To account for fluctuating susceptibility, we analyzed menstrual cycles rather than exposures until infection following virus challenges. We first reanalyzed infection data of 41 macaques receiving placebo or no treatment during once ( n=18) or twice ( n=23) weekly virus exposures. The same number of cycles was required for infection with either challenge frequency, while it took a median four or six challenges for once or twice weekly exposures, respectively. More virus challenges to infection likely reflect frequent unsuccessful exposures in frequently exposed animals. When reanalyzing two previously reported biomedical HIV intervention studies, we found 1% tenofovir gel was 74% or 86% efficacious based on cycles or exposures ( p=0.019 or p=0.003, respectively, Fisher's exact test), while 1% raltegravir gel was 84% or 89 % efficacious, respectively ( p=0.047 or p=0.031). Evaluating the number of menstrual cycles rather than exposures until infection can account for varying susceptibility during the menstrual cycle. Our observations have implications for future study designs such as planning the frequency of virus exposures. Menstrual cycle analysis may also avoid potential overestimation of efficacy against vaginal challenges during low susceptibility periods in the cycle that are unlikely to cause infection. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
20. Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
- Author
-
Dobard, Charles W., Sharma, Sunita, Cong, Mian-er, West, Rolieria, Makarova, Natalia, Holder, Angela, Chou-Pong Pau, Hanson, Debra L., Novembre, Francis J., Garcia-Lerma, Jose Gerardo, and Heneine, Walid
- Subjects
- *
HIV prevention , *TENOFOVIR , *MACAQUES , *GENETIC mutation , *PYROPHOSPHATES , *DISEASES , *THERAPEUTICS - Abstract
Background: Topically delivered tenofovir (TFV) from intravaginal rings, tablets, or gels is being evaluated for HIV prevention. We previously demonstrated that TFV delivered vaginally by gel protected macaques from vaginal infection with SHIV. Here we investigated efficacy of the TFV gel against vaginal transmission of a TFV-resistant SHIV containing the K65R mutation (SHIV162P3K65R) and its relationship to drug levels in vaginal tissues. Results: SHIV162P3K65R shows approximately a 5-fold reduction in susceptibility to TFV compared to wild-type SHIV. Efficacy was evaluated in pig-tailed macaques exposed vaginally twice-weekly (up to 10 weeks) to SHIV162P3K65R 30 min after receiving placebo (n = 6) or 1% TFV (n = 6) gel. Four of the six controls were infected after a median of 5 exposures. In contrast, five of six macaques that received TFV gel remained uninfected after 20 vaginal SHIV162P3K65R exposures, resulting in an estimated efficacy of 75%. The mean intracellular TFV-diphosphate (TFV-DP) concentrations in vaginal lymphocytes 4 h after a single gel dose were found to be high (1,631 fmol/106 cells, range 492-3,847) and within the in vitro IC75 range (1,206 fmol/106 cells) for SHIV162P3K65R. Conclusion: Both the modest resistance conferred by K65R and the high TFV-DP exposure in vaginal lymphocytes, likely explain the observed protection. The findings in this model do not predict complete loss of protection by topical TFV against vaginal exposure to HIV-1K65R viruses and provide a tissue drug target for high efficacy. These data will facilitate the development of TFV delivery platforms that have high activity on both wild-type and TFV-resistant viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Short Communication: Viremic Control Is Independent of Repeated Low-Dose SHIVSF162p3 Exposures.
- Author
-
Henning, Tara R., Hanson, Debra, Vishwanathan, Sundaram A., Butler, Katherine, Dobard, Charles, Garcia-Lerma, Gerardo, Radzio, Jessica, Smith, James, McNicholl, Janet M., and Kersh, Ellen N.
- Abstract
The repeat low-dose virus challenge model is commonly used in nonhuman primate studies of HIV transmission and biomedical preventions. For some viruses or challenge routes, it is uncertain whether the repeated exposure design might induce virus-directed innate or adaptive immunity that could affect infection or viremic outcomes. Retrospective cohorts of male Indian rhesus ( n=40) and female pigtail ( n=46) macaques enrolled in repeat low-dose rectal or vaginal SHIV
SF162p3 challenge studies, respectively, were studied to compare the relationship between the number of previous exposures and peak plasma SHIV RNA levels or viral load area under the curve (AUC), surrogate markers of viral control. Repeated mucosal exposures of 10 or 50 TCID50 of virus for rectal and vaginal exposures, respectively, were performed. Virus levels were measured by quantitative reverse-transcriptase real-time PCR. The cumulative number of SHIVSF162p3 exposures did not correlate with observed peak virus levels or with AUC in rectally challenged rhesus macaques [peak: rho (ρ)=0.04, p=0.8; AUC: ρ=0.33, p=0.06] or vaginally challenged pigtail macaques (peak: ρ=−0.09, p=0.7; AUC: ρ=0.11, p=0.6). Infections in these models occur independently of exposure history and provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia. These data also indicate that both the vaginal and rectal repeated low-dose virus exposure models using SHIVSF162p3 provide a reliable system for nonhuman primate studies. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
22. Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors.
- Author
-
Dobard, Charles, Sharma, Sunita, Parikh, Urvi M., West, Rolieria, Taylor, Andrew, Martin, Amy, Chou-Pong Pau, Hanson, Debra L., Lipscomb, Jonathan, Smith, James, Novembre, Francis, Hazuda, Daria, Garcia-Lerma, J. Gerardo, and Heneine, Walid
- Published
- 2014
- Full Text
- View/download PDF
23. High Susceptibility to Repeated, Low-Dose, Vaginal SHIV Exposure Late in the Luteal Phase of the Menstrual Cycle of Pigtail Macaques.
- Author
-
Vishwanathan, Sundaram A, Guenthner, Patricia C, Lin, Carol Y, Dobard, Charles, Sharma, Sunita, Adams, Debra R, Otten, Ron A, Heneine, Walid, Hendry, R Michael, McNicholl, Janet M, and Kersh, Ellen N
- Published
- 2011
- Full Text
- View/download PDF
24. Requirement for Integrase during Reverse Transcription of Human Immunodeficiency Virus Type 1 and the Effect of Cysteine Mutations of Integrase on Its Interactions with Reverse Transcriptase.
- Author
-
Kai Zhu, Dobard, Charles, and Chow, Samson A.
- Subjects
- *
HIV , *VIRAL replication , *GENETIC mutation , *DNA replication , *VIRAL genomes , *GENETICS - Abstract
Retroviral integrase catalyzes the essential step of integrating a double-stranded DNA copy of the viral genome into a host cell chromosome. Mutational studies have revealed that integrase is involved in additional steps of viral replication, but the mechanism for the pleiotropic effect is not well characterized. Since Cys residues generally play crucial roles in protein structure and function, we introduced Cys-to-Ser substitutions at positions 56, 65, and 130 of human immunodeficiency virus type 1 (HIV-1) integrase to determine their effects on integration activity and viral replication. None of the substitutions significantly affected the enzymatic activities in vitro. When introduced into the NLA-3 molecular clone of HIV-1, mutant viruses encoding Cys mutations at positions 56 and 65 of integrase replicated similarly to the wild-type virus in CD4+-T-cell lines, whereas the C130S-containing virus was noninfectious. The entry and postintegration steps of the viral life cycle for all mutant viruses were normal, and all had particle-associated reverse transcriptase (RT) activity. However, early reverse-transcribed DNA products were absent in the lysate of cells infected with the C130S mutant virus, indicating that the mutation abolished the ability of the virus to initiate endogenous reverse transcription. Coimmunoprecipitation using purified integrase and RT showed that the C-terminal domain of wild-type HIV-1 integrase interacted with RT. The interaction between integrase and RT was not affected in the presence of a reducing or alkylating agent, suggesting that the interaction did not involve a disulfide linkage. The C130S substitution within the core region may disrupt the protein recognition interface of the C-terminal domain and abolish its ability to interact with RT. Our results indicate that integrase plays an important role during the reverse-transcription step of the viral life cycle, possibly through physical interactions with RT. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
25. Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention.
- Author
-
Jhunjhunwala, Kunal, Dobard, Charles W., Sharma, Sunita, Makarova, Natalia, Holder, Angela, Dinh, Chuong, Mitchell, James, Wang, Lin, Zhang, Junmei, Patel, Sravan Kumar, Heneine, Walid, and Rohan, Lisa C.
- Subjects
- *
HIV prevention , *SUPPOSITORIES , *ANTI-HIV agents , *ANAL sex , *RECTAL administration , *ATAZANAVIR , *SIMIAN immunodeficiency virus , *ANTIRETROVIRAL agents - Abstract
Receptive anal intercourse (RAI) contributes significantly to HIV acquisition underscoring the need to develop HIV prevention options for populations engaging in RAI practices. We explored the feasibility of formulating rectal suppositories with potent antiviral drugs for on-demand use. A fixed-dose combination of tenofovir (TFV) and elvitegravir (EVG) (40 mg each) was co-formulated in six different suppository bases (three fat- and three water-soluble). Fat-soluble witepsol H15 and water-soluble polyethylene glycol (PEG) based suppositories demonstrated favorable in vitro release and were advanced to assess in vivo pharmacokinetics following rectal administration in macaques. In vivo drug release profiles were similar for both suppository bases. Median concentrations of TFV and EVG detected in rectal fluids at 2 h were 1- and 2-logs higher than the in vitro IC50, respectively; TFV-diphosphate levels in rectal tissues met or exceeded those associated with high efficacy against rectal simian HIV (SHIV) exposure in macaques. Leveraging on these findings, a PEG-based suppository with a lower dose combination of tenofovir alafenamide (TAF) and EVG (8 mg each) was developed and found to achieve similar rectal drug exposures in macaques. This study establishes the utility of rectal suppositories as a promising on-demand strategy for HIV PrEP and supports their clinical development. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model.
- Author
-
Dobard, Charles, Taylor, Andrew, Sharma, Sunita, Chuong, Dinh, Pau, Chou-Pong, Rohan, Lisa, and McGowan, Ian
- Abstract
An abstract of the article "Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model" by Charles Dobard, Andrew Taylor, Sunita Sharma, Dinh Chuong, Chou-Pong Pau, Lisa Rohan, Ian McGowan, and Walid Heneine is presented.
- Published
- 2014
- Full Text
- View/download PDF
27. Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in Tissue.
- Author
-
Dobard, Charles, Sharma, Sunita, Martin, Amy, Chou-Pong Pau, Holder, Angela, Kuklenyik, Zsuzsanna, Lipscomb, Jonathan, Hanson, Debra L., Smith, James, Novembre, Francis J., Gerardo García-Lerma, J., and Heneine, Walid
- Subjects
- *
SIMIAN immunodeficiency virus , *HIV infections , *THERAPEUTICS - Abstract
An abstract of the study "Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in Tissue," by Charles Dobard and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
28. Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine.
- Author
-
Parikh, Urvi M., Dobard, Charles, Sharma, Sunita, Cong, Mian-Er, Hongwei Jia, Martin, Amy, Chou-Pong Pau, Hanson, Debra L., Guenthner, Patricia, Smith, James, Kersh, Ellen, Garcia-Lerma, J. Gerardo, Novembre, Francis J., Otten, Ron, Folks, Thomas, and Heneine, Walid
- Subjects
- *
HIV prevention , *ANTISEPTICS , *ANIMAL models in research , *MACAQUES , *T cells , *THERAPEUTICS - Abstract
New-generation gels that deliver potent antiretroviral drugs against human immunodeficiency virus type 1 have renewed hopes for topical prophylaxis as a prevention strategy. Previous preclinical research with monkey models suggested that high concentrations and drug combinations are needed for high efficacy. We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and emtricitabine (FTC), by using a twice-weekly repeat challenge macaque model and showed that a preexposure vaginal application of gel with 1% TFV alone or in combination with 5% FTC fully protected macaques from a total of 20 exposures to simian-human immunodeficiency virus SF162p3. FTC and TFV were detected in plasma 30 min after vaginal application, suggesting rapid absorption. FTC was detected more frequently than TFV and showed higher levels, reflecting the fivefold-higher concentration of this drug than of TFV. Two of 12 repeatedly exposed but protected macaques showed limited T-cell priming, which did not induce resistance to infection when macaques were rechallenged. Thus, single drugs with durable antiviral activity can provide highly effective topical prophylaxis and overcome the need for noncoital use or for drug combinations which are more complex and costly to formulate and approve. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
29. Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques
- Author
-
Cong, Mian-er, Youngpairoj, Ae S., Aung, Wutyi, Sharma, Sunita, Mitchell, James, Dobard, Charles, Heneine, Walid, and Garcia-Lerma, J. Gerardo
- Subjects
- *
DRUG resistance , *HIV , *EMTRICITABINE , *TENOFOVIR , *INFECTIOUS disease transmission , *MACAQUES , *VIRION - Abstract
Abstract: Transmission of drug-resistant HIV has been widely documented. We generated tenofovir (TFV)- and emtricitabine (FTC)-resistant SHIV162P3 mutants that can be used to investigate the transmission efficiency of drug-resistant viruses and their impact on the efficacy of pre-exposure prophylaxis. Both SHIV162p3M184V and SHIV162p3K65R replicated in vitro at high titers. Drug resistance profiles were similar to those seen in HIV. Virus infectivity to virion particle ratios were 4- and 10-fold lower in SHIV162p3M184V and SHIV162p3K65R, compared to a concurrently generated WT SHIV162p3, respectively. Mucosal transmissibility studies using a repeat low-dose macaque model of rectal and vaginal transmission showed that both mutants were able to efficiently infect macaques only after the dose was increased to adjust for fitness reductions due to K65R and M184V. Our results in limited number of macaques suggest that the reduction in fitness due to M184V and K65R decreases virus transmissibility, and identify in vitro infectivity parameters that associate with mucosal transmissibility. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
30. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
- Author
-
Daly, Michele B., Sterling, Mara, Holder, Angela, Dinh, Chuong, Nishiura, Kenji, Khalil, George, García-Lerma, J. Gerardo, and Dobard, Charles
- Subjects
- *
MACAQUES , *RHESUS monkeys , *MEDROXYPROGESTERONE , *HIV prevention , *TENOFOVIR , *UNPLANNED pregnancy , *ACETATES - Abstract
Prevention of HIV infection and unintended pregnancies are public health priorities. In sub-Saharan Africa, where HIV prevalence is highest, depot medroxyprogesterone acetate (DMPA) is widely used as contraception. Therefore, understanding potential interactions between DMPA and antiretrovirals is critical. Here, we use a macaque model to investigate the effect of DMPA on the pharmacology of the antiretroviral tenofovir alafenamide (TAF). Female rhesus macaques received 30 mg of DMPA (n = 9) or were untreated (n = 9). Macaques received a human equivalent dose of TAF (1.5 mg/kg) orally by gavage. Tenofovir (TFV) and TFV-diphosphate (TFV-DP) were measured in blood, secretions, and tissues over 72 h. The median area under the curve (AUC 0–72h) values for TFV-DP in peripheral blood mononuclear cells were similar in DMPA-treated (6991 fmol*h/106 cells) and untreated controls (5256 fmol*h/106 cells) (P = 0.174). Rectal tissue TFV-DP concentrations from DMPA+ animals [median: 20.23 fmol/mg of tissue (range: 4.94–107.95)] were higher than the DMPA- group [median: below the limit of quantification (BLOQ-11.92)], (P = 0.019). TFV-DP was not detectable in vaginal tissue from either group. A high-dose DMPA treatment in macaques was associated with increased rectal TFV-DP levels, indicating a potential tissue-specific drug-drug interaction. The lack of detectable TFV-DP in the vaginal tissue warrants further investigation of PrEP efficacy with single-agent TAF products. DMPA did not affect systemic TAF metabolism, with similar PBMC TFV-DP in both groups, suggesting that DMPA use should not alter the antiviral activity of TAF. • We assessed pharmacological interactions between depot-medroxyprogesterone acetate (DMPA) and tenofovir alafenamide (TAF). • DMPA does not significantly affect systemic TAF metabolism. • TAF had limited penetration in the vaginal compartment. • The active metabolite of TAF was significantly increased in rectal tissue after DMPA treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
- Author
-
Dobard CW, Peet MM, Nishiura K, Holder A, Dinh C, Mitchell J, Khalil G, Pan Y, Singh ON, McCormick TJ, Agrahari V, Gupta P, Jonnalagadda S, Heneine W, Clark MR, García-Lerma JG, and Doncel GF
- Subjects
- Animals, Female, Adenine, Fumarates therapeutic use, Macaca, Tenofovir therapeutic use, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Pre-Exposure Prophylaxis
- Abstract
Background: Vaginal products for HIV prevention that can be used on-demand before or after sex may be a preferable option for women with low frequency or unplanned sexual activity or who prefer not to use daily or long-acting pre-exposure prophylaxis (PrEP). We performed dose ranging pharmacokinetics (PK) and efficacy studies of a vaginally applied insert containing tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG) in macaques under PrEP or post-exposure prophylaxis (PEP) modalities., Methods: PK studies were performed in 3 groups of pigtailed macaques receiving inserts with different fixed-dose combinations of TAF and EVG (10/8, 20/16 and 40/24 mg). PrEP and PEP efficacy of a selected insert was investigated in a repeat exposure vaginal SHIV transmission model. Inserts were administered 4 h before (n = 6) or after (n = 6) repeated weekly SHIV exposures. Infection outcome was compared with macaques receiving placebo inserts (n = 12)., Findings: Dose ranging studies showed rapid and sustained high drug concentrations in vaginal fluids and tissues across insert formulations with minimal dose proportionality. TAF/EVG (20/16 mg) inserts were selected for efficacy evaluation. Five of the 6 animals receiving these inserts 4 h before and 6/6 animals receiving inserts 4 h after SHIV exposure were protected after 13 challenges (p = 0.0088 and 0.0077 compared to placebo, respectively). The calculated PrEP and PEP efficacy was 91.0% (95% CI = 32.2%-98.8%) and 100% (95% CI = undefined), respectively., Interpretation: Inserts containing TAF/EVG provided high protection against vaginal SHIV infection when administered within a 4 h window before or after SHIV exposure. Our results support the clinical development of TAF/EVG inserts for on-demand PrEP and PEP in women., Funding: Funded by CDC intramural funds, an interagency agreement between CDC and USAID (USAID/CDC IAA AID-GH-T-15-00002), and by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Agency for International Development (USAID) under a Cooperative Agreement (AID-OAA-A-14-00010) with CONRAD/Eastern Virginia Medical School., Competing Interests: Declaration of interests J.G.G.-L. and W.H. are named in US. Government (USG) patents on “Inhibition of HIV infection through chemoprophylaxis” and in US. Government patent applications on “HIV postexposure prophylaxis” and “HIV pre-exposure prophylaxis”. W.H. and J.G.G.-L. report royalties or licenses from Mylan, Laurus Generics, TAD Pharma, and CIPLA Limited. M.M.P., O.N.S., T.J.C., V.A., P.G., S.J., G.F.D., and M.R.C. are named in patent applications on “Pharmaceutical compositions and methods of making on demand solid dosage formulations,” inventions that were developed under USAID-funded cooperative agreements. C.W.D., K.N., A.H., C.D., J.M., G.K., and Y.P. report no conflicts. The findings and conclusions of this manuscript are those of the authors and do not necessarily represent the official views of CDC, USAID, PEPFAR, EVMS, or the USG., (Published by Elsevier B.V.)
- Published
- 2022
- Full Text
- View/download PDF
32. Short Communication: Practical Experience with Analysis and Design of Repeat Low-Dose SHIVSF162P3 Exposure Studies in Female Pigtail Macaques with Varying Susceptibility During Menstrual Cycling.
- Author
-
Kersh EN, Henning TR, Dobard C, Heneine W, and McNicholl JM
- Subjects
- Administration, Topical, Animals, Disease Susceptibility, Female, Macaca nemestrina, Placebos administration & dosage, Treatment Outcome, Anti-Infective Agents, Local administration & dosage, Anti-Retroviral Agents administration & dosage, Disease Transmission, Infectious prevention & control, Menstrual Cycle immunology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome transmission, Simian Immunodeficiency Virus growth & development
- Abstract
Vaginal SHIVSF162P3 acquisition in pigtail macaques (Macaca nemestrina) is dependent on time point during the menstrual cycle. Susceptibility is higher around menstruation and lower at ovulation in mid cycle. This complicates the design of repeat low-dose (RLD) SHIV exposure studies because virus challenges given during low susceptibility periods have lower chances to infect. To account for fluctuating susceptibility, we analyzed menstrual cycles rather than exposures until infection following virus challenges. We first reanalyzed infection data of 41 macaques receiving placebo or no treatment during once (n=18) or twice (n=23) weekly virus exposures. The same number of cycles was required for infection with either challenge frequency, while it took a median four or six challenges for once or twice weekly exposures, respectively. More virus challenges to infection likely reflect frequent unsuccessful exposures in frequently exposed animals. When reanalyzing two previously reported biomedical HIV intervention studies, we found 1% tenofovir gel was 74% or 86% efficacious based on cycles or exposures (p=0.019 or p=0.003, respectively, Fisher's exact test), while 1% raltegravir gel was 84% or 89 % efficacious, respectively (p=0.047 or p=0.031). Evaluating the number of menstrual cycles rather than exposures until infection can account for varying susceptibility during the menstrual cycle. Our observations have implications for future study designs such as planning the frequency of virus exposures. Menstrual cycle analysis may also avoid potential overestimation of efficacy against vaginal challenges during low susceptibility periods in the cycle that are unlikely to cause infection.
- Published
- 2015
- Full Text
- View/download PDF
33. Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.
- Author
-
Tsegaye TS, Butler K, Luo W, Radzio J, Srinivasan P, Sharma S, Aubert RD, Hanson DL, Dobard C, Garcia-Lerma JG, Heneine W, McNicholl JM, and Kersh EN
- Subjects
- Administration, Oral, Administration, Topical, Animals, Drug Combinations, Drug Resistance, Viral, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, Female, Pre-Exposure Prophylaxis, Reassortant Viruses drug effects, Simian Immunodeficiency Virus drug effects, Simian Immunodeficiency Virus immunology, Anti-HIV Agents therapeutic use, Deoxycytidine analogs & derivatives, HIV Infections prevention & control, Macaca nemestrina, Organophosphorus Compounds, Simian Acquired Immunodeficiency Syndrome prevention & control, T-Lymphocytes physiology
- Abstract
Background: Preexposure prophylaxis (PrEP) for HIV prevention is a novel biomedical prevention method. We have previously modeled PrEP during rectal SHIV exposures in macaques and identified that Simian/Human Immunodeficiency Virus chimera (SHIV)-specific T-cell responses were induced in the presence of antiretroviral drugs, an observation previously termed T-cell chemo-vaccination. This report expands those initial findings by examining a larger group of macaques that were given oral or topical PrEP during repeated vaginal virus exposure., Methods: Thirty-six female pigtail macaques received up to 20 repeat low-dose vaginal inoculations with wild-type (WT) SHIVSF162P3 (n = 24) or a clonal derivative with the tenofovir (TFV) K65R drug-resistant mutation (n = 12). PrEP consisted of oral Truvada (n = 6, WT), TFV vaginal gel (n = 6, K65R), or TFV intravaginal ring (n = 6, WT). The remaining animals were PrEP-inexperienced controls (n = 12, WT; n = 6, K65R). SHIV-specific T cells were identified and characterized using interferon γ Enzyme-Linked ImmunoSpot (ELISPOT) and multiparameter flow cytometry., Results: Of 9 animals that were on PrEP and remained uninfected during WT SHIV vaginal challenges, 8 (88.9%) developed virus-specific T-cell responses. T cells were in CD4 and CD8 compartments, reached up to 4900 interferon γ-producing cells per million peripheral blood mononuclear cells, and primarily pol directed. In contrast, the replication-impaired K65R virus did not induce detectable T-cell responses, likely reflecting the need for adequate replication., Conclusions: Virus-specific T-cell responses occur frequently in oral or topical PrEP-protected pigtail macaques after vaginal exposure to WT SHIV virus. The contribution of such immune responses to protection from infection during and after PrEP warrants further investigation.
- Published
- 2015
- Full Text
- View/download PDF
34. Short communication: Viremic control is independent of repeated low-dose SHIVSF162p3 exposures.
- Author
-
Henning TR, Hanson D, Vishwanathan SA, Butler K, Dobard C, Garcia-Lerma G, Radzio J, Smith J, McNicholl JM, and Kersh EN
- Subjects
- Animals, Cohort Studies, Disease Models, Animal, Female, Macaca mulatta, Macaca nemestrina, Male, RNA, Viral blood, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, HIV immunology, Simian Acquired Immunodeficiency Syndrome immunology, Simian Acquired Immunodeficiency Syndrome virology, Simian Immunodeficiency Virus immunology, Viral Load
- Abstract
The repeat low-dose virus challenge model is commonly used in nonhuman primate studies of HIV transmission and biomedical preventions. For some viruses or challenge routes, it is uncertain whether the repeated exposure design might induce virus-directed innate or adaptive immunity that could affect infection or viremic outcomes. Retrospective cohorts of male Indian rhesus (n=40) and female pigtail (n=46) macaques enrolled in repeat low-dose rectal or vaginal SHIV(SF162p3) challenge studies, respectively, were studied to compare the relationship between the number of previous exposures and peak plasma SHIV RNA levels or viral load area under the curve (AUC), surrogate markers of viral control. Repeated mucosal exposures of 10 or 50 TCID50 of virus for rectal and vaginal exposures, respectively, were performed. Virus levels were measured by quantitative reverse-transcriptase real-time PCR. The cumulative number of SHIV(SF162p3) exposures did not correlate with observed peak virus levels or with AUC in rectally challenged rhesus macaques [peak: rho (ρ)=0.04, p=0.8; AUC: ρ=0.33, p=0.06] or vaginally challenged pigtail macaques (peak: ρ=-0.09, p=0.7; AUC: ρ=0.11, p=0.6). Infections in these models occur independently of exposure history and provide assurance that neither inoculation route nor number of exposures required for infection correlates with postinfection viremia. These data also indicate that both the vaginal and rectal repeated low-dose virus exposure models using SHIV(SF162p3) provide a reliable system for nonhuman primate studies.
- Published
- 2014
- Full Text
- View/download PDF
35. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada.
- Author
-
Cong ME, Youngpairoj AS, Zheng Q, Aung W, Mitchell J, Sweeney E, Hanson DL, Hendry RM, Dobard C, Heneine W, and García-Lerma JG
- Subjects
- Animals, Cell Line, Deoxycytidine pharmacology, Drug Combinations, Drug Resistance, Viral, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, HIV genetics, Humans, Macaca mulatta, Simian Acquired Immunodeficiency Syndrome prevention & control, Simian Immunodeficiency Virus genetics, Antiviral Agents pharmacology, Deoxycytidine analogs & derivatives, HIV drug effects, Mutation, Organophosphorus Compounds pharmacology, Simian Acquired Immunodeficiency Syndrome transmission, Simian Immunodeficiency Virus drug effects
- Abstract
Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prevention strategy recently found to reduce HIV incidence among men who have sex with men. We used a macaque model of HIV transmission to investigate if Truvada maintains prophylactic efficacy against an FTC-resistant isolate containing the M184V mutation. Five macaques received a dose of Truvada 3 days before exposing them rectally to the simian/human immunodeficiency virus mutant SHIV162p3(M184V), followed by a second dose 2 h after exposure. Five untreated animals were used as controls. Virus exposures were done weekly for up to 14 weeks. Despite the high (>100-fold) level of FTC resistance conferred by M184V, all five treated animals were protected from infection, while the five untreated macaques were infected (P = 0.0008). Our results show that Truvada maintains high prophylactic efficacy against an FTC-resistant isolate. Increased susceptibility to tenofovir due to M184V and other factors, including residual antiviral activity by FTC and/or reduced virus fitness due to M184V, may all have contributed to the observed protection.
- Published
- 2011
- Full Text
- View/download PDF
36. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques.
- Author
-
Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, Otten RA, Heneine W, Hendry RM, McNicholl JM, and Kersh EN
- Subjects
- Animals, Disease Susceptibility, Female, HIV-1, Macaca nemestrina, Pregnancy, Simian Immunodeficiency Virus, Viral Load, Viremia, Luteal Phase physiology, Simian Acquired Immunodeficiency Syndrome transmission, Vagina virology
- Abstract
Fluctuations in susceptibility to HIV or SHIV during the menstrual cycle are currently not fully documented. To address this, the time point of infection was determined in 19 adult female pigtail macaques vaginally challenged during their undisturbed menstrual cycles with repeated, low-dose SHIV(SF162P3) exposures. Eighteen macaques (95%) first displayed viremia in the follicular phase, as compared with 1 macaque (5%) in the luteal phase (P < 0.0001). Due to a viral eclipse phase, we estimated a window of most frequent virus transmission between days 24 and 31 of the menstrual cycle, in the late luteal phase. Thus, susceptibility to vaginal SHIV infection is significantly elevated in the second half of the menstrual cycle when progesterone levels are high and when local immunity may be low. Such susceptibility windows have been postulated before but not definitively documented. Our data support the findings of higher susceptibility to HIV in women during progesterone-dominated periods including pregnancy and contraceptive use.
- Published
- 2011
- Full Text
- View/download PDF
37. Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core.
- Author
-
Briones MS, Dobard CW, and Chow SA
- Subjects
- Amino Acid Substitution genetics, Gene Deletion, HIV Integrase genetics, Humans, Protein Binding, Cyclophilin A metabolism, HIV Core Protein p24 metabolism, HIV Integrase physiology, HIV-1 physiology, Virus Internalization, Virus Replication
- Abstract
After membrane fusion with a target cell, the core of human immunodeficiency virus type 1 (HIV-1) enters into the cytoplasm, where uncoating occurs. The cone-shaped core is composed of the viral capsid protein (CA), which disassembles during uncoating. The underlying factors and mechanisms governing uncoating are poorly understood. Several CA mutations can cause changes in core stability and a block at reverse transcription, demonstrating the requirement for optimal core stability during viral replication. HIV-1 integrase (IN) catalyzes the insertion of the viral cDNA into the host genome, and certain IN mutations are pleiotropic. Similar to some CA mutants, two IN mutants, one with a complete deletion of IN (NL-DeltaIN) and the other with a Cys-to-Ser substitution (NL-C130S), were noninfectious, with a replication block at reverse transcription. Compared to the wild type (WT), the cytoplasmic CA levels of the IN mutants in infected cells were reduced, suggesting accelerated uncoating. The role of IN during uncoating was examined by isolating and characterizing cores from NL-DeltaIN and NL-C130S. Both IN mutants could form functional cores, but the core yield and stability were decreased. Also, virion incorporation of cyclophilin A (CypA), a cellular peptidyl-prolyl isomerase that binds specifically to CA, was decreased in the IN mutants. Cores isolated from WT virus depleted of CypA had an unstable-core phenotype, confirming a role of CypA in promoting optimal core stability. Taken together, our results indicate that IN is required during uncoating for maintaining CypA-CA interaction, which promotes optimal stability of the viral core.
- Published
- 2010
- Full Text
- View/download PDF
38. Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription.
- Author
-
Dobard CW, Briones MS, and Chow SA
- Subjects
- Catalysis, Cell-Free System chemistry, Cell-Free System metabolism, Cell-Free System virology, DNA Primers chemistry, DNA Primers metabolism, HIV Integrase chemistry, HIV Reverse Transcriptase chemistry, HIV-1 chemistry, Humans, Nucleotides chemistry, Nucleotides metabolism, RNA, Transfer, Lys chemistry, RNA, Transfer, Lys metabolism, Virus Integration physiology, HIV Integrase metabolism, HIV Reverse Transcriptase metabolism, HIV-1 metabolism, Reverse Transcription physiology, Virus Replication physiology
- Abstract
Reverse transcriptase (RT) and integrase (IN) are two essential enzymes that play a critical role in synthesis and integration of the retroviral cDNA, respectively. For human immunodeficiency virus type 1 (HIV-1), RT and IN physically interact and certain mutations and deletions of IN result in viruses defective in early steps of reverse transcription. However, the mechanism by which IN affects reverse transcription is not understood. We used a cell-free reverse transcription assay with different primers and compositions of deoxynucleoside triphosphates to differentially monitor the effect of IN on the initiation and elongation modes of reverse transcription. During the initiation mode, addition of IN stimulated RT-catalyzed reverse transcription by fourfold. The stimulation was specific to IN and could not be detected when the full-length IN was replaced with truncated IN derivatives. The IN-stimulated initiation was also restricted to the template-primer complex formed using tRNA(3)(Lys) or short RNA oligonucleotides as the primer and not those formed using DNA oligonucleotides as the primer. Addition of IN also produced a threefold stimulation during the elongation mode, which was not primer dependent. The stimulation of both initiation and elongation by IN was retained in the presence of an RT trap. Furthermore, IN had no effect on steps at or before template-primer annealing, including packaging of viral genomic RNA and tRNA(3)(Lys). Taken together, our results showed that IN acts at early steps of reverse transcription by increasing the processivity of RT and suppressing the formation of the pause products.
- Published
- 2007
- Full Text
- View/download PDF
39. Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase.
- Author
-
Zhu K, Dobard C, and Chow SA
- Subjects
- Cell Line, Cysteine, DNA, Viral biosynthesis, Disulfides chemistry, HIV Integrase chemistry, Humans, Structure-Activity Relationship, Virus Assembly, Virus Replication, HIV Integrase physiology, HIV Reverse Transcriptase physiology, HIV-1 genetics, Transcription, Genetic
- Abstract
Retroviral integrase catalyzes the essential step of integrating a double-stranded DNA copy of the viral genome into a host cell chromosome. Mutational studies have revealed that integrase is involved in additional steps of viral replication, but the mechanism for the pleiotropic effect is not well characterized. Since Cys residues generally play crucial roles in protein structure and function, we introduced Cys-to-Ser substitutions at positions 56, 65, and 130 of human immunodeficiency virus type 1 (HIV-1) integrase to determine their effects on integration activity and viral replication. None of the substitutions significantly affected the enzymatic activities in vitro. When introduced into the NL4-3 molecular clone of HIV-1, mutant viruses encoding Cys mutations at positions 56 and 65 of integrase replicated similarly to the wild-type virus in CD4(+)-T-cell lines, whereas the C130S-containing virus was noninfectious. The entry and postintegration steps of the viral life cycle for all mutant viruses were normal, and all had particle-associated reverse transcriptase (RT) activity. However, early reverse-transcribed DNA products were absent in the lysate of cells infected with the C130S mutant virus, indicating that the mutation abolished the ability of the virus to initiate endogenous reverse transcription. Coimmunoprecipitation using purified integrase and RT showed that the C-terminal domain of wild-type HIV-1 integrase interacted with RT. The interaction between integrase and RT was not affected in the presence of a reducing or alkylating agent, suggesting that the interaction did not involve a disulfide linkage. The C130S substitution within the core region may disrupt the protein recognition interface of the C-terminal domain and abolish its ability to interact with RT. Our results indicate that integrase plays an important role during the reverse-transcription step of the viral life cycle, possibly through physical interactions with RT.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.